Galectin Therapeutics (GALT) Accumulated Expenses (2010 - 2026)

Galectin Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 665.27% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.2 million (up 665.27% YoY), while the FY2025 annual figure was $4.7 million, down 42.44% from the prior year.
• Accumulated Expenses was $4.2 million for Q1 2026 at Galectin Therapeutics, down from $4.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $10.9 million in Q2 2024 to a low of $300000.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $4.1 million across 5 years, with a median of $1.1 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses jumped 2893.33% in 2023, then slumped 93.81% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $9.1 million in 2022, then plunged by 87.54% to $1.1 million in 2023, then soared by 626.66% to $8.2 million in 2024, then slumped by 42.44% to $4.7 million in 2025, then declined by 11.35% to $4.2 million in 2026.
• The last three Accumulated Expenses figures came in at $4.2 million (Q1 2026), $4.7 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.